ERYtech Pharma Announces Clinical Trial Authorizations In Finland And Spain For Its European Phase 2b Study In AML

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ERYTECH Pharma (Paris:ERYP) (Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces it received authorizations for its Phase IIb GRASPA-ML clinical trial in Acute Myeloid Leukemia (AML) in Finland and Spain.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC